Церетон®

General characteristics. Structure:

Active agent of sincaline альфосцерат in terms of 100% substance – 400 mg;
excipients: глицерол - 50 mg, the water purified - before obtaining mass of contents of 590 mg;
structure of the capsule: gelatin, sorbitol, глицерол, methylparahydroxybenzoate, пропилпарагидроксибензоат, titanium dioxide, dye ferrous oxide yellow, the water purified.

Opisaniye:kapsula gelatinous soft, oval form, color, yellow or yellow with a light brown shade. Contents of capsules - the oily transparent colourless or slightly painted liquid.

Pharmacological properties:

Pharmacodynamics. Nootropic means. The central holinostimulyator as a part of which 40,5% of metabolic protected sincaline contain. Metabolic protection promotes release of sincaline in a brain. Provides synthesis of acetylcholine and phosphatidylsincaline in neyronalny membranes, improves a blood stream and strengthens metabolic processes in the central nervous system, activates a reticular formation. Increases the linear speed of a blood-groove on the party of traumatic damage of a brain, contributes to normalization of spatio-temporal characteristics of spontaneous bioelectric activity of a brain, regress of focal neurologic symptoms and recovery of consciousness; exerts positive impact on cognitive and behavioural reactions of patients with vascular diseases of a brain (distsirkulyatorny encephalopathy and the residual phenomena of disturbance of cerebral circulation). Has preventive and corrective effect on pathogenetic factors of an involutional psychoorganic syndrome, changes phospholipidic structure of membranes of neurons: participates in phosphatidylsincaline synthesis (membrane phospholipid), improves plasticity of neyronalny membranes. Stimulates dozozavisimy allocation of acetylcholine in physiological conditions, improves synoptic transfer, function of receptors. Does not exert impact on a reproductive cycle and does not possess teratogenic, mutagen action.

Pharmacokinetics. At parenteral reception (10 mg/kg) Tsereton® preferential collects in a brain, lungs and a liver. Absorption - 88%, easily gets through a blood-brain barrier (at oral administration concentration in a brain - 45% of that in plasma). Lungs excrete 85% of drug in the form of carbon dioxide, other quantity (15%) is removed by kidneys and through intestines.

Indications to use:

- The recovery period of a severe craniocereberal injury and ischemic stroke, the recovery period of a hemorrhagic stroke proceeding with focal polusharny symptomatology or simptomatm of defeat of a brainstem;
- a psychoorganic syndrome against the background of degenerative and involutional changes of a brain;
- cognitive frustration (disturbances of cogitative function, memory, confusion of consciousness, a disorientation, decrease in motivation, initiative and ability to concentration of attention), including at dementia and encephalopathy;
- senile pseudo-melancholy.

Route of administration and doses:

In the recovery period of a craniocereberal injury, ischemic or hemorrhagic stroke of Tsereton® appoint 800 mg in the morning and 400 mg in the afternoon within 6 months.
At chronic cerebrovascular insufficiency and syndromes of dementia of Tsereton® appoint 400 mg (1 capsule) 3 times a day, preferably after food, within 3-6 months.

Features of use:

Церетон® does not exert impact on the speed of psychomotor reactions.

Side effects:

Emergence of nausea is possible (mainly, as a result of dofaminergichesky activation). Does not demand cancellation, rather temporary dose decline of drug.
Allergic reactions.

Interaction with other medicines:

Significant interaction with other drugs is not revealed.

Contraindications:

- Hypersensitivity to drug;
- acute stage of a hemorrhagic stroke;
- pregnancy;
- breastfeeding period;
- children up to 18 years (due to the lack of data).

Overdose:

Nausea can be noted. Treatment: symptomatic therapy.

Storage conditions:

List B. In the place protected from light at a temperature not above 25 °C. To store in the place, unavailable to children. A period of validity - 3 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Capsules of 400 mg. On 14 capsules in a blister strip packaging.
On 1 or 2 blister strip packagings together with the application instruction place in a pack from a cardboard.